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Abstract
The role of IFN-g in reducing the intracellular load of Bordetella pertussis in murine macrophages in vitro has been examined.
The results demonstrate that exposure to IFN-g can reduce bacterial load in viable macrophages and that this is associated with
production of nitric oxide (NO). These observations provide a mechanism by which IFN-g may mediate its antimicrobial effect
and support an important role for activated alveolar macrophages in the elimination of B. pertussis from the respiratory tract.
Using intracellular iron chelation, it is shown that intracellular survival of B. pertussis is dependant on iron availability and
suggest that iron restriction may be an important mechanism by which IFN-g influences bacterial survival within mouse
macrophages. It is also shown that IFN-g may mediate its effect through NO independent mechanisms and that B. pertussis is
sensitive to agents that stimulate the respiratory burst. Finally, it is shown that the concentration of L-tryptophan may be a
limiting step in the intracellular survival of B. pertussis and that the induction of tryptophan degrading enzymes may be an
additional mechanism through which IFN-g exerts its antimicrobial effects against B. pertussis. © 1999 Elsevier Science B.V. All
rights reserved.
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1. Introduction
Infection of the respiratory tract by the gram-nega-
tive bacterium Bordetella pertussis results in whooping
cough, an important cause of morbidity and mortality
in human infants. It is well known that during coloniza-
tion of the respiratory tract this bacterium can specifi-
cally adhere to ciliated epithelium, however, it is now
clear that B. pertussis can exploit both extracellular and
intracellular niches during infection. Persistence of B.
pertussis within murine and rabbit alveolar
macrophages has been described [1,2], and the ability of
B. pertussis to invade and survive within human
macrophages and other cell types has recently been
documented by a number of groups [3–6], suggesting
that intracellular localization may be an important
mechanism in the disease process.
Protective immunity induced by previous infection or
immunization with whole cell pertussis (Pw) and new
generation acellular pertussis (Pa) vaccines can protect
against whooping cough. The roles of B cells, T cells,
and IFN-g in immunity to B. pertussis using normal
mice or gene knockout mice have previously been ex-
amined, and it was demonstrated that protective immu-
nity involves both cell mediated and humoral
mechanisms [7–11]. Adoptive transfer of CD4 Th1
cells from convalescent mice conferred protection
against B. pertussis challenge in T cell deficient athymic
mice providing evidence that T cells play a significant
role in protection. Aerosol challenge of naive IFN-g
receptor knockout mice resulted in an atypical dissemi-
nated disease, demonstrating an important role for this
cytokine in confining the bacterium to the respiratory
tract during infection of naive animals. Furthermore,
studies in wildtype mice and in Ig: mice prior to or
after bacterial challenge revealed that protection early
after immunization with Pa is mediated by antibody
against multiple protective antigens [10]. However, the
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more complete protection conferred by previous infec-
tion or following immunization with Pw reflects the
induction of Th1 cells [9]. In the present study the in
vitro mechanisms by which IFN-g may mediate these
effects have been examined.
2. Materials and methods
2.1. Growth of B. pertussis
B. pertussis W28 phase I were grown as previously
described [10–12], all cultures were in exponential-
phase growth at the time of use.
2.2. B. pertussis infection of murine macrophages
The mouse macrophage-like cell line J774 in expo-
nential growth phase was used in all studies. Cells were
washed out of culture medium and resuspended by
agitation in a small volume of B. pertussis transport
medium containing freshly prepared bacteria at a ratio
of 10 bacteria per macrophage, a ratio which did not
induce macrophage apoptosis. After a 1-h incubation,
cells were washed three times in antibiotic-free RPMI
1640 (Gibco, Paisley, UK) to remove unbound bacte-
ria. Cells were then incubated for 40 min at 37°C in a
Gentamycin (50 mg:ml):Polymyxin B (20 mg:ml) solu-
tion in RPMI 1640, which killed extracellular bacteria
(5 log10 CFU reduction) but was found to have limited
effect on numbers of intracellular bacteria (0.5 log10
CFU reduction). Infected macrophages were then
washed a further six times before culturing for 48 h at
37°C, 5% CO2. In test cultures different concentrations
of recombinant murine IFN-g (a kind gift from A.
Meagher, NIBSC, Herts, UK) were added to
macrophage cultures. At 48 h cells were harvested and
the bacterial load assessed. Macrophages remained \
80% viable using this protocol except when high con-
centrations of IFN-g were used (\400 ng:ml), this was
important as loss of macrophage viability can lead to
artefacts in bactericidal assays [10]. Macrophage viabil-
ity was determined by acridine orange:ethidium bro-
mide viable cell counting from sample wells.
2.3. NO2 assay
Cell free supernatants from macrophage cultures
were sampled 24 h after establishment of cultures using
the Greiss assay as previously described [13]
2.4. E6aluation of arginine analogues on the
bactericidal acti6ity of IFN-g
Infected and uninfected macrophage cultures were
also performed in the presence of 100 mM N-
monomethyl-L-arginine (L-NMMA) or N-
monomethyl-D-arginine (D-NMMA) (Calbiochem,
Nottingham, UK) added to cultures at 0, 6 and 12 h
after infection.
2.5. E6aluation of L-tryptophan, and iron chelation on
the bactericidal acti6ity of IFN-g
Infected and uninfected macrophage cultures were
also established in the presence of either 1 mM L-tryp-
tophan (Sigma, Dorset, UK); or 50 mM deferoxamine
mesylate (Sigma) an intracellular iron chelator [14].
Using these concentrations no decrease was seen in
macrophage viability over the course of the experiment.
2.6. Induction of the respiratory burst by methylene
blue
Methylene blue (Sigma), an agent that induces the
respiratory burst [15], was added to selected cultures 1
h after infection to a concentration of 104 M, a
concentration which did not influence macrophage
viability.
2.7. Assessment of bacterial load
Bacterial load was assessed by removal of 100 ml of
lysed macrophages from individual cultures. These were
spotted in triplicate onto each of three Bordet–Gengou
agar plates and the number of CFU was estimated after
5 days of incubation. Results are reported as the mean
viable B. pertussis from at least three samples per
experimental group, and are expressed as CFU per
viable macrophage. This avoided potential artefacts due
to loss of macrophage viability during the course of
bactericidal assays [16].
3. Results
3.1. IFN-g reduces macrophage bacterial load in 6itro.
The mechanisms underlying the established role of
IFN-g in limiting B. pertussis infection were investi-
gated in vitro. The murine macrophage-like cell line
J774 was infected with virulent B. pertussis at a ratio of
10 bacteria per macrophage and exposed to varying
concentrations of murine IFN-g. Fig. 1 shows that at
concentrations between 3.2 and 80 ng:ml IFN-g re-
duced the intracellular load of B. pertussis over 48 h of
in vitro culture. At high concentrations (400 ng:ml and
above) the bacterial load appeared to increase, how-
ever, this was accompanied by a loss of macrophage
viability and presumably bacterial release into the cul-
ture supernatant.
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Fig. 1. IFN-g reduces macrophage bacterial load in vitro. Bordetella
pertussis-infected macrophages were cultured with recombinant
murine IFN-g at concentrations ranging between 0 and 400 ng:ml, in
the absence (vertical shading) or presence of 100 mM N-monomethyl-
L-arginine (L-NMMA) (horizontal shading) or 100 mM N-
monomethyl-D-arginine (D-NMMA) (open bars).
Fig. 3. IFN-g acts through more than one mechanism. Bordetella
pertussis-infected macrophages were cultured in the absence (open
bars) or presence (horizontal shading) of 50 ng:ml recombinant
murine IFN-g. To determine the mechanisms of IFN-g action
macrophages were treated with medium (control), or with exogenous
1 mM L-tryptophan, the intracellular iron chelator deferoxamine
mesylate (iron chelation) or methylene blue an inducer of the respira-
tory burst. ND, not determined.
3.2. IFN-g induces nitric oxide (NO) release from B.
pertussis infected cells in 6itro
Exposure of B. pertussis infected macrophages to
IFN-g resulted in the production of NO as measured by
NO2 release (Fig. 2), which was suppressed by addi-
tion of the competitive inhibitor L-NMMA, but not by
D-NMMA [17]. Addition of these compounds to cul-
tures of infected macrophages in the presence or ab-
sence of IFN-g (Fig. 1) showed that D-NMMA had
little or no effect on bacterial load. Incorporation of
L-NMMA resulted in an increase in bacterial load
compared to controls, however, it did not fully suppress
the effect of IFN-g. These results suggest that while the
production of NO may contribute to B. pertussis killing
there are likely to be other bactericidal mechanisms in
operation.
3.3. IFN-g may also act through NO-independent
mechanisms.
Treatment of macrophages with methylene blue, an
electron carrier and an inhibitor of guanylate cyclase
[15], enhanced the killing of intracellular B. pertussis
(Fig. 3). However, addition of catalase, superoxide
dismutase or mannitol, inhibitors of the effects of su-
peroxide anions, hydrogen peroxide or hydroxyl radi-
cals had no effect on bacterial recovery (data not
shown). Treatment of mouse macrophages with the
intracellular iron chelator, deferoxamine mesylate, in-
hibited the intracellular growth of B. pertussis (Fig. 3).
Taken together these results indicate that the intracellu-
lar survival of B. pertussis is dependant on iron
availability and suggest that iron restriction may be an
important mechanism by which IFN-g influences bacte-
rial survival within mouse macrophages. IFN-g is also
known to induce intracellular L-tryptophan depletion
by activation of indoleamine 2,3-dioxygenase [18,19].
Addition of L-tryptophan to infected macrophage cul-
tures in the absence of IFN-g, resulted in an increased
bacterial load compared to controls, although this was
reduced in the presence of IFN-g. This suggests that the
concentration of L-tryptophan may be a limiting step in
Fig. 2. IFN-g induces nitric oxide (NO) release from Bordetella
pertussis-infected cells in vitro. NO2
 was measured by Greiss assay
from 24 h supernatants sampled from B. pertussis-infected
macrophages, cultured with recombinant murine IFN-g at concentra-
tions ranging between 0 and 400 ng:ml (open squares). Similar
samples were taken from non-infected control cultures (solid squares)
or infected cultures incubated in the presence of 100 mM N-
monomethyl-L-arginine (L-NMMA) (open cicles) or 100 mM N-
monomethyl-D-arginine (D-NMMA) (solid circles).
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the intracellular survival of B. pertussis and that this
may be an additional mechanism through which IFN-g
exerts its antimicrobial effect.
4. Discussion
Like most successful bacterial pathogens, B. pertussis
appears to have adapted adversarial strategies to delay,
overcome or evade most of the immune effector mecha-
nisms deployed by the host (Table 1). Previously the
authors and others have described an important role
for IFN-g in the immune response to pertussis [7–
11,20], in the present study the potential mechanism by
which these effects may be mediated in vitro have been
examined. The demonstration that IFN-g reduced the
intracellular load of B. pertussis over 48 h of in vitro
culture is consistent with findings by others who have
described an antimicrobial effect for IFN-g [20–23]. It
has been shown that this effect was associated with the
production of NO, a potent antibacterial agent, as
measured by nitrite production. The results using an
intracellular iron chelator suggest that the intracellular
survival of B. pertussis is dependant on iron availabil-
ity. It is known that reactive nitrogen intermediates
cause intracellular iron loss by inhibiting various iron-
dependent enzymes, it may be that iron restriction is an
important mechanism by which IFN-g influences bacte-
rial survival within murine macrophages. Whilst the
association between the reduction of bacterial load and
NO in this study, and between NO and Pw by others
[24,25], suggests an antibacterial role for reactive nitro-
gen intermediates, other IFN-g induced mechanisms are
also likely to be in operation. Incorporation of L-
NMMA, a competitive inhibitor for NO production
[17], but not the analogue D-NMMA, dramatically
reduced nitrite concentrations in infected macrophage
cultures but did not completely abolish the bactericidal
effects of IFN-g. Furthermore production of high con-
centrations of NO in response to high levels of IFN-g,
resulted in reduced viability of cultured macrophages.
This suggests that NO may be inducing macrophage
death. Interestingly recent reports have implicated NO
in B. pertussis-mediated pathology to the respiratory
epithelium [26].
Methylene blue, an electron carrier and an inhibitor
of guanylate cyclase, known to stimulate the respiratory
burst [15] enhanced the killing of intracellular B. pertus-
sis. However, addition of inhibitors of the effects of
superoxide anions, hydrogen peroxide or hydroxyl radi-
cals, important mediators of the respiratory burst, had
no effect on bacterial recovery. Another mechanism
through which IFN-g can mediate its antimicrobial
effect is by activation of indoleamine 2,3-dioxygenase
which depletes intracellular L-tryptophan [18,19]. Addi-
tion of L-tryptophan to B. pertussis-infected cultures
resulted in enhanced bacterial load indicating that the
concentration of L-tryptophan may be a limiting step in
the intracellular survival of B. pertussis. This may be an
additional mechanism through which IFN-g exerts its
antimicrobial effects against this pathogen.
Recent studies have shown that depletion of alveolar
macrophages results in increased numbers of B. pertus-
sis in the lungs during the early phase of infection [27]
and a critical role for IFN-g during this period has
previously been described [11]. The results described
herein, provide a mechanism by which IFN-g may
mediate this antimicrobial effect and support an impor-
tant role for activated alveolar macrophages in the
elimination of B. pertussis from the respiratory tract.
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